We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+17%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.33B
AUM Growth
+$1.78B
(+24%)
Cap. Flow
+$552M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
20.52%
Holding
814
New
78
Increased
378
Reduced
271
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$50.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$39.4M |
| 3 |
Intel
INTC
|
+$29.2M |
| 4 |
Qualcomm
QCOM
|
+$27.6M |
| 5 |
Danaher
DHR
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$49.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$41.6M |
| 3 |
ARQL
Arqule Inc
ARQL
|
+$26.5M |
| 4 |
Arrowhead Research
ARWR
|
+$24.9M |
| 5 |
Merck
MRK
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.73% |
| 2 | Technology | 19.55% |
| 3 | Financials | 10.18% |
| 4 | Consumer Discretionary | 9.32% |
| 5 | Communication Services | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PARA
226
DELISTED
Paramount Global Class B
PARA
| $9.31M | 0.1% |
+221,894
| New | +$8.59M |
|
227
Equinix
EQIX
$103B
| $9.29M | 0.1% |
15,923
+9,549
| +150% | +$5.37M |
|
228
Afya
AFYA
$1.3B
| $9.26M | 0.1% |
341,500
+114,500
| +50% | +$3.09M |
|
229
Baker Hughes
BKR
$60.1B
| $9.19M | 0.1% |
358,694
+135,597
| +61% | +$3.08M |
|
230
Cadence Design Systems
CDNS
$93.4B
| $9.1M | 0.1% |
131,142
+54,004
| +70% | +$3.62M |
|
231
Citizens Financial Group
CFG
$30.1B
| $9.07M | 0.1% |
223,468
+2,879
| +1% | +$108K |
|
232
Monster Beverage
MNST
$93.2B
| $9.06M | 0.1% |
285,076
-209,716
| -42% | -$6.16M |
|
|
FOLD
233
DELISTED
Amicus Therapeutics
FOLD
| $9.05M | 0.1% |
929,500
-46,500
| -5% | -$426K |
|
|
CTXS
234
DELISTED
Citrix Systems Inc
CTXS
| $9.05M | 0.1% |
81,623
+6,825
| +9% | +$734K |
|
|
INST
235
DELISTED
Instructure, Inc.
INST
| $9.03M | 0.1% |
+187,301
| New | +$8.79M |
|
|
BPMC
236
DELISTED
Blueprint Medicines
BPMC
| $8.91M | 0.1% |
+111,191
| New | +$8.32M |
|
237
Entergy
ETR
$53.1B
| $8.86M | 0.1% |
147,976
-16,428
| -10% | -$968K |
|
238
Pan American Silver
PAAS
$18.6B
| $8.86M | 0.1% |
+374,000
| New | +$6.93M |
|
239
Synopsys
SNPS
$74.5B
| $8.86M | 0.09% |
63,632
+55,895
| +722% | +$7.67M |
|
240
Automatic Data Processing
ADP
$102B
| $8.81M | 0.09% |
51,700
+3,148
| +6% | +$521K |
|
241
Synchrony
SYF
$24.5B
| $8.7M | 0.09% |
241,692
+11,287
| +5% | +$404K |
|
|
SJR
242
DELISTED
Shaw Communications Inc.
SJR
| $8.68M | 0.09% |
427,090
+5,802
| +1% | +$117K |
|
243
Credicorp
BAP
$31.1B
| $8.65M | 0.09% |
40,600
-700
| -2% | -$147K |
|
|
DERM
244
DELISTED
Dermira, Inc.
DERM
| $8.64M | 0.09% |
570,000
+220,000
| +63% | +$1.9M |
|
245
MGM Resorts International
MGM
$11.8B
| $8.57M | 0.09% |
257,599
+74,284
| +41% | +$2.26M |
|
246
Take-Two Interactive
TTWO
$45.3B
| $8.52M | 0.09% |
69,569
+5,083
| +8% | +$619K |
|
247
Lear
LEA
$7.26B
| $8.48M | 0.09% |
61,782
+2,767
| +5% | +$343K |
|
248
D.R. Horton
DHI
$41.3B
| $8.43M | 0.09% |
159,744
+73,533
| +85% | +$3.93M |
|
249
GE Aerospace
GE
$375B
| $8.42M | 0.09% |
151,405
-9,039
| -6% | -$467K |
|
250
Nektar Therapeutics
NKTR
$2.41B
| $8.33M | 0.09% |
25,733
-267
| -1% | -$77.4K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2019 Portfolio in Review
As of Q4 2019, Candriam SCA held 814 positions worth $9.33B, up 24% from $7.55B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA deployed $552M of net new capital in Q4 2019, opening 78 new positions and adding to 378 existing holdings. Its largest new stake was Vipshop: 2,005,000 shares worth $28.4M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $49.9M trimmed.
- Candriam SCA's largest Q4 2019 buy was Vipshop: 2,005,000 shares worth $28.4M.
- Candriam SCA added most to Microsoft in Q4 2019, an estimated $50.3M increase.
- Candriam SCA's biggest Q4 2019 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $49.9M.
- Candriam SCA fully exited Hilton Worldwide in Q4 2019, selling an estimated $11.8M.
- Candriam SCA's ten largest holdings make up 21% of its $9.33B portfolio in Q4 2019.
- Candriam SCA opened 78 new positions and closed 33 in Q4 2019.
- Candriam SCA's portfolio value rose 24% quarter-over-quarter to $9.33B.
Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.